Home Other Building Blocks Zomepirac Sodium Salt

Zomepirac Sodium Salt

CAS No.:
64092-48-4
Catalog Number:
AG003VF2
Molecular Formula:
C15H13ClNNaO3
Molecular Weight:
313.7114
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
100mg
99%
1 week
United States
$140
- +
500mg
99%
1 week
United States
$190
- +
Product Description
Catalog Number:
AG003VF2
Chemical Name:
Zomepirac Sodium Salt
CAS Number:
64092-48-4
Molecular Formula:
C15H13ClNNaO3
Molecular Weight:
313.7114
MDL Number:
MFCD00057223
IUPAC Name:
sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate
InChI:
InChI=1S/C15H14ClNO3.Na/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10;/h3-7H,8H2,1-2H3,(H,18,19);/q;+1/p-1
InChI Key:
SEEXPXUCHVGZGU-UHFFFAOYSA-M
SMILES:
[O-]C(=O)Cc1cc(c(n1C)C(=O)c1ccc(cc1)Cl)C.[Na+]
EC Number:
264-669-2
UNII:
DA5B6IWF46
Properties
Complexity:
385  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
313.048g/mol
Formal Charge:
0
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
313.713g/mol
Monoisotopic Mass:
313.048g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
62.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs. Toxicology in vitro : an international journal published in association with BIBRA 20120301
Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3. PloS one 20120101
Single dose oral fenoprofen for acute postoperative pain in adults. The Cochrane database of systematic reviews 20110101
Single dose oral mefenamic acid for acute postoperative pain in adults. The Cochrane database of systematic reviews 20110101
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters 20101101
Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. Chemical research in toxicology 20070601
A simple in vitro model to study the stability of acylglucuronides. Journal of pharmacological and toxicological methods 20070101
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug metabolism and disposition: the biological fate of chemicals 20060101
In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. Chemical research in toxicology 20051101
I almost crossed over. Texas medicine 20051001
Photolysis of NSAIDs. IV. Photoproducts of zomepirac determined by LC-ESI-MS. Biomedical chromatography : BMC 20041201
Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. Drug metabolism and disposition: the biological fate of chemicals 20031101
India ink staining after sodium dodecyl sulfate polyacrylamide gel electrophoresis and in conjunction with Western blots for peptide mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid communications in mass spectrometry : RCM 20020101
Hepatic covalent adduct formation with zomepirac in the CD26-deficient mouse. Journal of gastroenterology and hepatology 20020101
Investigating the TNP-OVA and direct popliteal lymph node assays for the detection of immunostimulation by drugs associated with anaphylaxis in humans. Journal of applied toxicology : JAT 20020101
Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides. Life sciences 20011121
Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life sciences 20010105
Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. Journal of pharmacokinetics and biopharmaceutics 19940201
Reversible renal failure and nephrotic syndrome without interstitial nephritis from zomepirac. American journal of kidney diseases : the official journal of the National Kidney Foundation 19851001
Zomepirac-induced anaphylactic shock: an under-reported phenomenon. The American journal of the medical sciences 19851001
Severe coronary spasm during zomepirac-induced allergic reaction. Southern medical journal 19840701
Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. The American journal of medicine 19840601
Focal renal cortical necrosis associated with zomepirac. The American journal of medicine 19840601
A zomepirac reaction mimicking ectopic pregnancy. Drug intelligence & clinical pharmacy 19840601
Interstitial nephritis and proteinuria associated with zomepirac. Clinical pharmacy 19840101
Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding. Clinical pharmacology and therapeutics 19831101
Zomepirac-induced renal failure. Archives of internal medicine 19830601
Nonoliguric renal failure associated with zomepirac. JAMA 19830401
Renal failure and tubular dysfunction due to zomepirac therapy. JAMA 19830121
Effect of zomepirac on experimental coronary artery thrombosis and ischemic myocardial injury in the conscious dog. Journal of cardiovascular pharmacology 19830101
Long-term therapy for the pain of osteoarthritis: a comparison of zomepirac sodium and aspirin. Journal of clinical pharmacology 19830101
Zomepirac-related acute renal failure. Drug intelligence & clinical pharmacy 19830101
Zomepirac, interstitial nephritis, and renal failure. Annals of internal medicine 19820901
Reversible nonoliguric acute renal failure associated with zomepirac therapy. Mayo Clinic proceedings 19820601
Anaphylactic shock, acute renal failure, and disseminated intravascular coagulation. Suspected complications of zomepirac. JAMA 19820226
Orally administered zomepirac and parenterally administered morphine. Comparison for the treatment of postoperative pain. JAMA 19801121
Long-term safety of zomepirac: a double-blind comparison with aspirin in patients with osteoarthritis. Journal of clinical pharmacology 19800101
Clinical analgesic assay of oral zomepirac and intramuscular morphine. NIDA research monograph 19790101
Properties